⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18458275 | 1.00 | CHRM5 (0.39) | — | |
| SCHEMBL13430643 | 1.00 | CHRM5 (0.39) | — | |
| SCHEMBL20491430 | 1.00 | CHRM5 (0.39) | — | |
| SCHEMBL14185446 | 1.00 | CHRM5 (0.39) | — | |
| SCHEMBL7113798 | 1.00 | CHRM5 (0.39) | — | |
| SCHEMBL10793 | 1.00 | — | — | |
| SCHEMBL1920139 | 1.00 | CHRM5 (0.39) | — | |
| SCHEMBL1345379 | 0.97 | — | — | |
| SCHEMBL5346771 | 0.97 | — | — | |
| SCHEMBL7846 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368092-A1 | 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-11-07 | — | — | US | disclosed |
| EP-4396181-A1 | 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS | Breye Therapeutics ApS (DK) | 2024-07-10 | — | — | EP | disclosed |
| EP-4385980-A1 | INDAZOLES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2024-06-19 | — | — | EP | disclosed |
| CN-114671865-B | Pleuromutilin derivative containing thiazole-pyridinylalkyl quaternary ammonium salt side chain, and preparation method and application thereof | 西咸新区沣厚原创医药科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-11999699-B2 | Substituted pyrazole amides | Grünenthal GmbH (DE) | 2024-06-04 | — | — | US | disclosed |
| CN-117881675-A | 2, 4-dihydro-3H-1, 2, 4-triazol-3-one P2X7 antagonists | 布雷耶疗法有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-110770214-B | Heterocyclic P2X7 antagonists | 布雷耶疗法有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | disclosed |
| WO-2023031319-A1 | 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS | AXXAM S.P.A. (IT) | 2023-03-09 | — | — | WO | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-1060178-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-1999045006-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 1999-09-10 | — | — | WO | disclosed |
| US-5308830-A | Low dosage; nonphytotoxic to crops; pre- and postemergence | ROHM AND HAAS COMPANY (US) | 1994-05-03 | — | — | US | disclosed |
| EP-0000951-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING 1-SUBSTITUTED IMIDAZOLES, 1-SUBSTITUTED IMIDAZOLES AND 1-SUBSTITUTED IMIDAZOLES FOR USE IN THE TREATMENT OR PROPHYLAXIS OF THROMBO-EMBOLIC DISORDERS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-23 | — | — | EP | disclosed |
| EP-0000950-B1 | IMIDAZOLE DERIVATIVES AND SALTS THEREOF AND THEIR SYNTHESIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-02-01 | — | — | EP | disclosed |
| US-4317830-A | ANTISHOCK AGENTS, ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1982-03-02 | — | — | US | disclosed |
| US-4284641-A | ANTITHROMBOEMBOLIC AGENT | BURROUGHS WELLCOME CO. (US) | 1981-08-18 | — | — | US | disclosed |
| EP-0000950-A1 | Imidazole derivatives and salts thereof and their synthesis | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | disclosed |
| EP-0000951-A1 | Pharmaceutical Formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | disclosed |